While the $118.3 billion raised by biopharma companies in 2021 through public and private transactions is 12% lower than the amount raised the prior year, it still represents an impressive financings record, led primarily by IPOs and venture capital rounds.

Canadian company Future Fertility Inc. is hatching plans to expand the user base for its flagship egg prediction software product, Violet, for egg cryopreservation. The noninvasive image analysis tool uses artificial intelligence (AI) to evaluate the reproductive potential of mature eggs. Investors are backing the Toronto-based company with $6 million in series A funds, so it can expand internationally and develop additional assessment products.

LONDON – Natural killer (NK) cell therapy specialist Onk Therapeutics Ltd. has raised $21.5 million in a series A, enabling it to move three lead programs into proof-of-concept animal testing and to progress manufacturing and scale-up of its cord blood-derived cells.

Investors including SOSV, Cultivate(MD), Wavemaker360 Health, Blu Venture Investors and Broad Street Angels are backing Strados Labs LLC with $4.5 million. The pre-series A funding will be used to accelerate development of the company’s smart sensor platform Resp. The funding comes after Strados received FDA clearance for the product in December 2021 and brings its total raised to $7 million.

PARIS – Milvue SAS completed a series A round, raising more than $9 million towards deployment of its artificial intelligence-based software solution used for diagnosis and full triage of osteoarticular pathologies in emergency departments.